Immix Biopharma closed a $93.7 million stock offering led by prominent U.S. biotechnology investors, enhancing its AL Amyloidosis treatments.
Quiver AI Summary
Immix Biopharma, Inc. has announced the successful closing of an underwritten registered offering of over 19 million shares of common stock priced at $5.10 per share, along with pre-funded warrants for 490,196 shares at $5.09 each. The offering, which garnered approximately $93.7 million in net proceeds after expenses, attracted prominent U.S. biotechnology institutional investors and mutual funds. Morgan Stanley served as the sole book-running manager, supported by Citizens Capital Markets and Mizuho as co-managers. The offering utilized a previously filed shelf registration statement with the SEC as part of the company's ongoing commitment to combat relapsed/refractory AL Amyloidosis, focusing on its lead therapy, NXC-201, which is currently in a multi-center study and has received special designations from the FDA and EMA.
Potential Positives
- Immix Biopharma successfully closed an underwritten registered offering, raising approximately $93.7 million, which can be used to support its ongoing research and development initiatives.
- The financing included investment from leading U.S. biotechnology institutional investors and mutual funds, indicating strong confidence from reputable sources in the company's future potential.
- Immix Biopharma's lead candidate, NXC-201, has received both Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA and Orphan Drug Designation (ODD), enhancing its development and commercialization prospects.
Potential Negatives
- The public offering price of $5.10 per share may indicate market skepticism about the company's valuation or financial stability, as it suggests a potentially low confidence level among investors.
- Relying on institutional investors and mutual funds for financing could imply that the company lacks sufficient internal funding or financial robustness to support its initiatives independently.
- The press release lacks detailed information about how the raised funds will specifically be utilized, which may leave investors uncertain about the company’s strategic direction and future growth prospects.
FAQ
What was the purpose of Immix Biopharma's recent stock offering?
Immix Biopharma's stock offering aimed to raise approximately $93.7 million for its operations and advancements in AL Amyloidosis treatments.
Who managed the underwriting for Immix Biopharma's offering?
Morgan Stanley served as the sole book-running manager, with Citizens Capital Markets and Mizuho acting as co-managers.
What are the key details of the common stock offered?
Immix Biopharma offered 19,117,646 shares at a price of $5.10 per share, along with pre-funded warrants for 490,196 shares.
What is Immix Biopharma's lead therapy candidate?
The lead candidate is NXC-201, a CAR-T cell therapy targeting relapsed/refractory AL Amyloidosis, designed to filter toxic light chains.
How has NXC-201 been recognized by regulatory authorities?
NXC-201 has received Regenerative Medicine Advanced Therapy designation and Orphan Drug Designation from the FDA and EMA.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IMMX Insider Trading Activity
$IMMX insiders have traded $IMMX stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IMMX stock by insiders over the last 6 months:
- GABRIEL S MORRIS (CFO) has made 2 purchases buying 4,825 shares for an estimated $10,192 and 0 sales.
- ILYA M RACHMAN (CEO and Chairman) has made 2 purchases buying 4,678 shares for an estimated $10,048 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IMMX Hedge Fund Activity
We have seen 19 institutional investors add shares of $IMMX stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CABLE CAR CAPITAL, LP removed 779,358 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,613,271
- CITADEL ADVISORS LLC added 89,798 shares (+inf%) to their portfolio in Q3 2025, for an estimated $187,677
- UNITED CAPITAL FINANCIAL ADVISORS, LLC added 70,682 shares (+inf%) to their portfolio in Q3 2025, for an estimated $147,725
- STATE STREET CORP added 56,000 shares (+130.4%) to their portfolio in Q3 2025, for an estimated $117,039
- MARSHALL WACE, LLP added 55,035 shares (+inf%) to their portfolio in Q3 2025, for an estimated $115,023
- IMPRINT WEALTH LLC added 41,209 shares (+157.2%) to their portfolio in Q3 2025, for an estimated $86,126
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 40,032 shares (+78.8%) to their portfolio in Q3 2025, for an estimated $83,666
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
– Financing includes leading U.S. biotechnology institutional investors and mutual funds –
LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase 490,196 shares of common stock at a price to the public of $5.09 per pre-funded warrant, which represents the per share public offering price for the common stock, less the $0.01 per share exercise price for each such pre-funded warrant. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $93.7 million.
The financing includes leading U.S. biotechnology institutional investors and mutual funds.
Morgan Stanley acted as the sole book-running manager for the offering. Citizens Capital Markets and Mizuho acted as co-managers for the offering.
The securities in the registered offering were offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-269100), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 3, 2023, and declared effective on January 11, 2023. A prospectus supplement and accompanying prospectus describing the terms of the registered offering was filed with the SEC and is available on its website at www.sec.gov . Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from: Morgan Stanley & Co. LLC, attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone: 1-866-718-1649 or by email: [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
Contacts
Mike Moyer
LifeSci Advisors
[email protected]
Company Contact
Gabriel Morris, CFO
[email protected]
